The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Alveolar hemorrhage (AH), diffuse AH (DAH)
Publications
Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors.
Journal of cardiovascular and thoracic research 2022;14;201-204 — 2022 — 201-204
A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.
Cases journal 2009 Jul 30;2;8553 — 2009 Jul 30 — 8553
Eptifibatide overdose.
International journal of cardiology 2009 Jan 24;131;430-2 — 2009 Jan 24 — 430-2
Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.
Journal of interventional cardiology 2006 Aug;19;356-63 — 2006 Aug — 356-63
Alveolar hemorrhage associated with periprocedural eptifibatide administration.
The Journal of invasive cardiology 2004 Jun;16;341-2 — 2004 Jun — 341-2